You might also like
iRhythm Technologies, Inc. (IRTC) is a healthcare technology company specializing in global ambulatory cardiac monitoring. The company provides innovative diagnostic services through its Zio platform, which includes wearable devices and data analytics to monitor and diagnose cardiac arrhythmias. IRTC's operations focus on delivering clinically validated solutions to improve patient outcomes and streamline healthcare workflows.
- Zio Services - Offers wearable cardiac monitoring devices, including the Zio XT and Zio Monitor, designed to detect and diagnose arrhythmias through continuous monitoring and advanced data analytics.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Quentin Blackford ExecutiveBoard | President, Chief Executive Officer, Director | Board Member at Alphatec Holdings, Inc. and Paragon 28, Inc. | Joined IRTC in October 2021. Former COO at Dexcom, CFO at NuVasive, and finance leader at Zimmer Holdings. Holds dual B.S. degrees in Accounting and Business Administration. Certified Public Accountant (inactive). | View Report → |
Chad Patterson Executive | Chief Commercial Officer | None | Joined IRTC in July 2022. Former EVP and CMO at Dexcom. Played a key role in Dexcom's revenue growth and global expansion. Holds an MBA from USC and a B.A. from Gonzaga University. | |
Daniel Wilson Executive | Chief Financial Officer | None | Joined IRTC in June 2019. Previously EVP of Corporate Development and Investor Relations. Former healthcare investment banker at J.P. Morgan and business development leader at Penumbra, Inc.. | |
Mervin Smith Executive | EVP of Business Operations | None | Joined IRTC in July 2023. Former VP & GM at Zimmer Biomet. Holds an MBA from Ball State University and a B.S. in Accounting from the University of Pittsburgh. | |
Minang Turakhia, M.D. Executive | Chief Medical Officer, Chief Scientific Officer, EVP of Product Innovation | Professor of Medicine (on leave) at Stanford University School of Medicine | Joined IRTC in June 2022. Renowned cardiologist and researcher. Played a key role in clinical research and product launches at IRTC. Holds an M.D. from Stanford University. | |
Patrick Murphy Executive | Chief Business Officer and Chief Legal Officer | None | Joined IRTC in November 2021. Former EVP and CLO at Dexcom. Extensive legal and corporate finance experience. Holds a J.D. from St. Louis University School of Law. | |
Sumi Shrishrimal Executive | Chief Risk Officer | None | Joined IRTC in May 2022. Former Chief Risk Officer at Dexcom and VP of Internal Audit at NuVasive. Holds a B.A. in Accounting and Information Systems from the University of Mumbai. | |
Abhijit Y. Talwalkar Board | Chairman of the Board | Board Member at AMD, TE Connectivity, and Lam Research; Chairman at Friends of the Children (Bay Area Chapter) | Chairman of IRTC since May 2016. Former CEO of LSI Corporation and senior leader at Intel. Holds a B.S. in Electrical Engineering from Oregon State University. | |
Brian Yoor Board | Director | Chairman at Covira Surgical; Audit Committee Chair at Confluent Medical | Director at IRTC since June 2023. Former CFO at Abbott Laboratories. Holds a B.B.A. in Accounting from the University of Toledo. | |
Bruce G. Bodaken Board | Director | None | Director at IRTC since July 2017. Former CEO of Blue Shield of California. Extensive experience in healthcare leadership. | |
C. Noel Bairey Merz, M.D. Board | Director | Medical Director at Cedars-Sinai Medical Center; Professor at UCLA | Director at IRTC since April 2018. Renowned cardiologist and researcher. Holds an M.D. from Harvard Medical School and a B.A. from the University of Chicago. | |
Karen Ling Board | Director | None | Director at IRTC since November 2021. Former EVP and Chief Human Resources Officer at AIG. Extensive experience in HR and corporate governance. | |
Mark J. Rubash Board | Director | Chairman of Intuitive Foundation; Board Member at Intuitive Surgical | Director at IRTC since March 2016. Former CFO at Shutterfly and senior finance leader at eBay. Holds a B.S. in Accounting from California State University, Sacramento. |
-
Given that international markets are contributing only 1% to growth in 2025 and are still in early stages, what are the key challenges you anticipate in scaling up outside the U.S., particularly in markets like Japan where commercial launch is expected mid-2025, and how confident are you in achieving meaningful international revenue?
-
With the proposed tariffs potentially impacting gross margins by 50 to 75 basis points due to component suppliers in Mexico and China, what specific measures are you taking to mitigate this headwind, and are alternative supply chain strategies being considered to offset these impacts?
-
You mentioned incurring significant expenses related to FDA remediation efforts and DOJ subpoena activities, with remediation expenses expected to be approximately $15 million in 2025; can you elaborate on the nature of these regulatory issues, how they are affecting your operations, and when you expect these costs and impacts to subside?
-
Zio AT saw particular strength in the fourth quarter due to a competitor's disruption in the marketplace; how sustainable is this growth if the competitor resolves their issues, and what strategies are in place to maintain or accelerate Zio AT's growth in a more competitive environment?
-
Despite exiting 2024 with strong momentum and 24% year-over-year growth, along with multiple catalysts like record account openings, primary care channel momentum, and Epic integration, your 2025 guidance appears conservative; can you clarify what potential upsides are excluded from your guidance and what factors might limit growth in 2025?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
BioTelemetry, Inc. | Acquired by Royal Philips, this company competes in providing remote cardiac monitoring technology and diagnostic services. They have developed patch-based cardiac monitors that have received FDA and foreign regulatory clearances. |
Preventice Solutions, Inc. | Acquired by Boston Scientific, Inc., this company offers remote cardiac monitoring technology and diagnostic services. They have developed patch-based cardiac monitors that have received FDA and foreign regulatory clearances. |
Bardy Diagnostics, Inc. | Acquired by Baxter International, Inc., this company provides remote cardiac monitoring technology and diagnostic services. They have developed patch-based cardiac monitors that have received FDA and foreign regulatory clearances. |
GE Healthcare | This company sells traditional, 24-to-48-hour Holter monitors and competes in the remote cardiac monitoring market. |
Philips Healthcare | This company sells traditional, 24-to-48-hour Holter monitors and competes in the remote cardiac monitoring market. |
Spacelabs Healthcare Inc. | This company sells traditional, 24-to-48-hour Holter monitors and competes in the remote cardiac monitoring market. |
Mortara Instrument, Inc. | Acquired by Hill-Rom Holdings, Inc., now part of Baxter International, Inc., this company sells traditional, 24-to-48-hour Holter monitors and competes in the remote cardiac monitoring market. |
Welch Allyn Holdings, Inc. | Acquired by Hill-Rom Holdings, Inc., now part of Baxter International, Inc., this company sells traditional, 24-to-48-hour Holter monitors and competes in the remote cardiac monitoring market. |
This company has added capabilities on their watch platform to measure non-continuous ECG and to alert users to the potential presence of irregular heartbeats suggestive of asymptomatic Afib. | |
Fitbit | This company has added capabilities on their watch platform to measure non-continuous ECG and to alert users to the potential presence of irregular heartbeats suggestive of asymptomatic Afib. |
| Customer | Relationship | Segment | Details |
|---|---|---|---|
Centers for Medicare & Medicaid Services (CMS) | Major payor of the company's Zio Services | All | Revenue: 24% of total revenue for 2024, 2023, and 2022. <br>Accounts Receivable: 15% (2024), 25% (2023). |
One Commercial Customer | Commercial payor of the company's services | All | Accounts Receivable: 13% as of Dec 31, 2024. |
No recent press releases or 8-K filings found for IRTC.